Adam Dell has joined Austin Ventures as a venture partner. He previously was founder and managing general partner of Impact Venture Partners and before that, he was a partner with Crosspoint Venture Partners. He also founded MessageOne.
2 min read · 17 May 2010
1 min read · 17 May 2010
2 min read · 17 May 2010
3 min read · 15 May 2010
NuPathe Inc., a Conshohocken, Penn.-based drug developer focused on the central nervous system, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol PATH, with Lazard Capital Markets and Leerink Swann serving as co-lead underwriters. The company reports $11.3 million in 2009 revenue and a $15.6 million net loss. NuPathe has raised $53 million in VC funding, from firms like Quaker BioVentures, Safeguard Scientifics, Battelle Ventures, Birchmere Ventures, S.R. One Ltd. www.nupathe.com
1 min read · 14 May 2010
CardioDx, a Palo Alto, Calif.-based provider of cardiovascular genomic diagnostics, has raised $5 million in Series D funding from the GE Healthymagination Fund. The investment is part of a larger round, which a regulatory filing suggests could be worth upwards of $45.5 million ($34.5m sold so far). Other shareholders include Kleiner Perkins Caufield & Byers, TPG Biotech, Intel Capital, MDV, DAG Ventures, Pappas Ventures and Asset Management Group.
4 min read · 14 May 2010
2 min read · 14 May 2010
Palmaz Scientific Inc., a Dallas-based developer metallurgical surface nanotech for the manufacture of implantable medical devices, has raised $3 million from the Texas Emerging Technology Fund.
6 min read · 13 May 2010
Healthcare Plus Supplies Inc., a Dallas-based supplier of durable medical equipment to local hospices and their patients, has raised $2.1 million in funding from Advantage Capital Partners.
3 min read · 13 May 2010
Sequent Medical Inc., an Aliso Viejo, Calif.-based maker of devices for endovascular treatment of neurovascular disease conditions, has raised $15.6 million in Series B funding. Domain Associates led the round, and was joined by return backers ersant Ventures and US Venture Partners.
2 min read · 13 May 2010
